Purple Biotech (XTAE:PPBT) Net Income From Continuing Operations : ₪-74.71 Mil (TTM As of Dec. 2023)

View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Purple Biotech's net income from continuing operations for the three months ended in Dec. 2023 was ₪-18.17 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-74.71 Mil.

Purple Biotech Net Income From Continuing Operations Historical Data

The historical data trend for Purple Biotech's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Net Income From Continuing Operations Chart

Purple Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-20.22

-107.33

-66.66

-81.38

-74.71

Purple Biotech Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-22.60	-18.34	-19.30	-18.90	-18.17

Purple Biotech Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-74.71 Mil.

Purple Biotech (XTAE:PPBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

PPBT:USA 1YI1:Germany

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.